Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global Castrate Resistant Prostate Cancer Therapeutics market size will reach 22,206 Million USD in 2025 and is projected to reach 49,460 Million USD by 2032, with a CAGR of 12.12% (2025-2032). Notably, the China Castrate Resistant Prostate Cancer Therapeutics market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Castrate-resistant prostate cancer (CRPC) therapeutics refer to treatments and therapies used to manage and combat prostate cancer that has progressed despite the suppression of testosterone levels, also known as castration. CRPC occurs when prostate cancer cells adapt and continue to grow despite the absence of testosterone, which is typically responsible for fueling their growth. The therapeutics for CRPC aim to target alternative pathways and mechanisms that allow the cancer cells to thrive and survive in the absence of testosterone. These therapies include hormone-based treatments, such as androgen receptor-targeted agents, as well as chemotherapy, immunotherapy, targeted molecular therapies, and radiopharmaceuticals. The goal of castrate-resistant prostate cancer therapeutics is to slow disease progression, manage symptoms, and potentially extend survival for patients with this advanced stage of prostate cancer.
The major global suppliers of Castrate Resistant Prostate Cancer Therapeutics include Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Hengrui Pharmaceuticals, CTTQ, Sanofi, Zhendong Pharmaceutical, Hansoh, Clovis Oncology, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Castrate Resistant Prostate Cancer Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Castrate Resistant Prostate Cancer Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Castrate Resistant Prostate Cancer Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Castrate Resistant Prostate Cancer Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Castrate Resistant Prostate Cancer Therapeutics Include:
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Zhendong Pharmaceutical
Hansoh
Clovis Oncology
Castrate Resistant Prostate Cancer Therapeutics Product Segment Include:
Hormonal Therapy
Chemotherapy
Others
Castrate Resistant Prostate Cancer Therapeutics Product Application Include:
Hospital
Specialty Clinic
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Castrate Resistant Prostate Cancer Therapeutics Industry PESTEL Analysis
Chapter 3: Global Castrate Resistant Prostate Cancer Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Castrate Resistant Prostate Cancer Therapeutics Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Castrate Resistant Prostate Cancer Therapeutics Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Castrate Resistant Prostate Cancer Therapeutics Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Castrate Resistant Prostate Cancer Therapeutics Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global Castrate Resistant Prostate Cancer Therapeutics market size will reach 22,206 Million USD in 2025 and is projected to reach 49,460 Million USD by 2032, with a CAGR of 12.12% (2025-2032). Notably, the China Castrate Resistant Prostate Cancer Therapeutics market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Castrate-resistant prostate cancer (CRPC) therapeutics refer to treatments and therapies used to manage and combat prostate cancer that has progressed despite the suppression of testosterone levels, also known as castration. CRPC occurs when prostate cancer cells adapt and continue to grow despite the absence of testosterone, which is typically responsible for fueling their growth. The therapeutics for CRPC aim to target alternative pathways and mechanisms that allow the cancer cells to thrive and survive in the absence of testosterone. These therapies include hormone-based treatments, such as androgen receptor-targeted agents, as well as chemotherapy, immunotherapy, targeted molecular therapies, and radiopharmaceuticals. The goal of castrate-resistant prostate cancer therapeutics is to slow disease progression, manage symptoms, and potentially extend survival for patients with this advanced stage of prostate cancer.
The major global suppliers of Castrate Resistant Prostate Cancer Therapeutics include Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Hengrui Pharmaceuticals, CTTQ, Sanofi, Zhendong Pharmaceutical, Hansoh, Clovis Oncology, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Castrate Resistant Prostate Cancer Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Castrate Resistant Prostate Cancer Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Castrate Resistant Prostate Cancer Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Castrate Resistant Prostate Cancer Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Castrate Resistant Prostate Cancer Therapeutics Include:
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Zhendong Pharmaceutical
Hansoh
Clovis Oncology
Castrate Resistant Prostate Cancer Therapeutics Product Segment Include:
Hormonal Therapy
Chemotherapy
Others
Castrate Resistant Prostate Cancer Therapeutics Product Application Include:
Hospital
Specialty Clinic
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Castrate Resistant Prostate Cancer Therapeutics Industry PESTEL Analysis
Chapter 3: Global Castrate Resistant Prostate Cancer Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Castrate Resistant Prostate Cancer Therapeutics Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Castrate Resistant Prostate Cancer Therapeutics Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Castrate Resistant Prostate Cancer Therapeutics Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Castrate Resistant Prostate Cancer Therapeutics Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Castrate Resistant Prostate Cancer Therapeutics Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Castrate Resistant Prostate Cancer Therapeutics Product by Type
- 1.2.1 Hormonal Therapy
- 1.2.2 Chemotherapy
- 1.2.3 Others
- 1.3 Castrate Resistant Prostate Cancer Therapeutics Product by Application
- 1.3.1 Hospital
- 1.3.2 Specialty Clinic
- 1.3.3 Others
- 1.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Analysis (2020-2032)
- 1.5 Castrate Resistant Prostate Cancer Therapeutics Market Development Status and Trends
- 1.5.1 Castrate Resistant Prostate Cancer Therapeutics Industry Development Status Analysis
- 1.5.2 Castrate Resistant Prostate Cancer Therapeutics Industry Development Trends Analysis
- 2 Castrate Resistant Prostate Cancer Therapeutics Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Castrate Resistant Prostate Cancer Therapeutics Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Castrate Resistant Prostate Cancer Therapeutics Market Analysis by Country
- 4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.5 China Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.6 France Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.14 India Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Castrate Resistant Prostate Cancer Therapeutics Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Revenue by Key Suppliers (2021-2025)
- 5.2 Castrate Resistant Prostate Cancer Therapeutics Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Castrate Resistant Prostate Cancer Therapeutics Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Castrate Resistant Prostate Cancer Therapeutics Market Analysis by Type
- 6.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Pfizer/Astellas (Xtandi)
- 7.1.1 Pfizer/Astellas (Xtandi) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Johnson & Johnson
- 7.2.1 Johnson & Johnson Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 AstraZeneca/Merck (Lynparza)
- 7.3.1 AstraZeneca/Merck (Lynparza) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Bayer
- 7.4.1 Bayer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Bayer Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Jiangsu Hengrui Pharmaceuticals
- 7.5.1 Jiangsu Hengrui Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 CTTQ
- 7.6.1 CTTQ Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 CTTQ Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Sanofi
- 7.7.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Sanofi Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Zhendong Pharmaceutical
- 7.8.1 Zhendong Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.8.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Hansoh
- 7.9.1 Hansoh Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Hansoh Castrate Resistant Prostate Cancer Therapeutics Product Portfolio
- 7.9.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Clovis Oncology
- 7.10.1 Clovis Oncology Basic Company Profile (Employees, Areas Service, Competitors and Contact I
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
